First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease

BACKGROUND: In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer’s disease (AD) after infusion of a humanized monoclonal antibody to amyloid β, AAB-003 (NCT01193608; re...

Descripción completa

Detalles Bibliográficos
Autores principales: Delnomdedieu, Marielle, Duvvuri, Sridhar, Li, David Jianjun, Atassi, Nazem, Lu, Ming, Brashear, H. Robert, Liu, Enchi, Ness, Seth, Kupiec, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772335/
https://www.ncbi.nlm.nih.gov/pubmed/26925577
http://dx.doi.org/10.1186/s13195-016-0177-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772335/
https://www.ncbi.nlm.nih.gov/pubmed/26925577
http://dx.doi.org/10.1186/s13195-016-0177-y

Ejemplares similares